

Press Release
Immediate Distribution

**LIVIA GROUP ANNOUNCES THE ACQUISITION OF PRIME EUROPEAN THERAPEUTICALS
S.P.A. FROM ALBANY MOLECULAR RESEARCH INC.**

Munich, 01.08.2019 – LIVIA Corporate Development SE announces the acquisition of Prime European Therapeutics S.p.A. (“Euticals”), from Albany Molecular Research Inc. (“AMRI”). Headquartered in Lodi, Italy, Euticals is specialized in custom synthesis and the manufacture of active pharmaceutical ingredients (“APIs”).

Euticals runs the Lodi API manufacturing facility with 90 employees and more than EUR 25m in annual sales. The manufacturing facilities in Rozzano and Origgio, Italy, previously owned by Euticals, will remain with AMRI. Eutical’s large portfolio of APIs holds a number of stable long-term standard care products serving patients and healthcare globally while the chemical technology portfolio is covering some of the most challenging reagents and reactions.

The business will be rebranded to operate as Archimica and will continue to offer small- to large-scale commercial manufacturing as well as analytical support for the global biopharmaceutical market.

“With the acquisition of Euticals, LIVIA has decided to engage in both the field of manufacture and development of generic APIs as well a difficult-to-handle chemical technology”, states Prof. Dr. Dr. Peter Löw, founder and owner of LIVIA Group. “The combination of a strong reliable product portfolio, the experience in developing APIs for pharmaceutical application and exceptional chemical technology presents a very attractive growth opportunity for Archimica”.

LIVIA Group is an independent industrial holding as well as the private investment enterprise of Prof. Dr. Dr. Peter Löw with funds under management of more than EUR 782m. LIVIA invests in a diverse spectrum of assets, ranging from corporate, agricultural and opportunistic investments to real estate, emerging markets, and fine arts/ antiques. More than 250 executed transactions made LIVIA's management a preferred and trusted partner of international corporations and financial institutions.

LIVIA Corporate Development is specialized in acquiring European corporate spin-offs / carve-outs as well as mid-sized companies with revenues between EUR 20m and EUR 1.5bn. The focus is on business transformations and acquisitions of underperforming companies with operational improvement potential as well as add-on acquisitions for existing platform investments to realize synergies.

www.livia-group.com

AMRI, a global contract research and manufacturing organization, partners with pharmaceutical and biotechnology companies to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI's team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development and Analytical Services and Fine Chemicals; API Manufacturing; and Drug Product. For more information about AMRI, visit www.amriglobal.com.